![[Chart]](http://ichart.europe.yahoo.com/c/0b/a/azn.l)
| | | Address: | 15 Stanhope Gate
London W1K 1LN United Kingdom | | Web Site: | www.astrazeneca.com | | Index: | OMXS30 | FTSE100 | STOXX50 | STOXX600 | |
Market Place(s)
: | Frankfurt | London | New York | |
Number Of Shares
: | 1,449,840,000 | | Sector: | Health | | Industry: | Pharmaceuticals | | Sub-Industry: | Pharmaceutical Products |
|
| | AstraZeneca, eradicating certain diseasesIn 1999, the British company, Zeneca plc, and the Swedish company, Astra, merged to form AstraZeneca, one of the world leaders in the pharmaceutical industry. The British group finishes and sells various medicines to pharmacies and hospitals.It operates in seven major therapy fields: anesthesia, cardiology, gastroenterology, pneumology, oncology, neurology and infection.Manufactured by the group, products such as Zomig or Seroquel are used to treat problems associated with the nervous system (migraine, schizophrenia, epilepsy), while Atacand, for example, is used in the treatment of cardiovascular problems such as hypertension, and Nexium or Losec for gastrointestinal disorders such as ulcers...not to mention the fields of oncology (where Zoladex and Tumadex are used to treat bowel and prostrate cancers), anesthesia (where Diprivan and Xylocaine are used in surgery), and respiratory disorders (where asthma, for example, is treated with Pulmicort).AstraZeneca's work does not, however, stop there. The group is also active in the non-pharmaceutical sector: its subsidiary Astra Tech finishes implants, dental implants for example, and various medical appliances.With its locations throughout the world (western and eastern Europe, Brazil, Canada, the United States, Asia) , AstraZeneca as a group makes a major contribution to the eradication of certain diseases, this on account of its excellent medicines, which are increasingly effective due to its sustained R&D (Research and Development) work. |
|
| ISIN: | GB0009895292 | | Reuters Code: | AZN.L | |
Local Code
: | AZN | | Auditor: | KPMG Audit Plc | | Number of employees: | 67,900 ( 31/12/2007 )
66,600 ( 31/12/2006 ) |
|
| Chairman of Board of Directors: | Louis Schweitzer | | Chief Executive Officer: | David R Brennan | | Chief Financial Officer: | SImon Lowth | | Data as of 31/12/2007. |
|
| Annual report: | 29/01/2010 | | Shareholder ’s meeting: | 30/04/2009 | | Profits 1st half-year: | 30/04/2009 |
|
| Capital Research and Management Company: | 4.89% | | Axa SA: | 4.87% | | Investor AB: | 4.36% | | Barclays Plc: | 4.24% | | Wellington Management Co: | 4.16% | | Legal & General Investment Management Ltd: | 4.06% |
|
| | |
Year
|
2007
|
2006
|
2005
|
2004
|
2003
| |
Net Operating revenues*
| 29,559 | 26,475 | 23,950 | 21,426 | 18,849 | |
Net Profit*
| 5,627 | 6,043 | 4,724 | 3,813 | 3,036 | | * in million(s) of
Pound
|
|
|
Year
|
2007
|
2006
|
2005
|
2004
|
2003
| |
Earnings per share*
| 3.74 | 3.86 | 2.91 | 2.28 | 1.78 | | * in
pence |
|
| Medicine for cardiovascular disorders: | 23% | | Medicine for gastrointestinal disorders: | 22% | | Antipsychotics: | 18% | | Medicine for cancer: | 16% | | Anti-inflammatory: | 13% | | Pain-relievers: | 6% | | Misc.: | 2% | | Sector Data as of 31/12/2007 |
|
| SALES PER GEOGRAPHIC AREA | |
| Core Market | | United States | 45 |
|
| Geographic areas | | North America: | 46% | | Europe: | 30% | | Rest of the World: | 15% | | Asia / Pacific: | 9% | | Areas data as of 31/12/2007 | | Profile as of 31/12/2007.
Data provided by EuroStockCity |
|
|
|
67.50 (2.49%) 
Profile
